PAVE Parallactic Visual-Field Enhancement for chronic visual field loss after stroke, brain injury, or brain surgery
Official title: PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss
Run by NeuroAEye LLC · NCT07185971 · Data updated 2026-11-12
This study will test whether using the PAVE virtual-reality headset can expand the visual field in adults with chronic vision loss following stroke, traumatic brain injury, or brain surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years to 80 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | NeuroAEye LLC Industry-sponsored |
| Locations | 2 sites (Cedar Rapids, Iowa and 1 other locations) |
| Status | Recruiting |
| Started | March 16, 2026 |
| Main results expected | July 2026 |
| Study ends | August 2026 |
| Registry record updated | April 2, 2026 |
| Trial ID | NCT07185971 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults 21–80 who are at least six months and no more than ten years post-stroke, traumatic brain injury, or brain surgery with a confirmed homonymous hemianopia or quadrantanopia and who can wear a VR headset and attend regular clinic sessions.
✕Probably not a fit
Patients with no residual vision, active ocular disorders or non-optic nerve field defects, insufficient fixation, interfering neurological or psychiatric conditions, recent injury under six months, use of conflicting visual therapies or certain medications, or implanted active medical devices are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-arm interventional study enrolls adults aged 21–80 with chronic homonymous hemianopia, quadrantanopia, or generalized constriction occurring 6 months to 10 years after stroke, TBI, or brain surgery. Participants will use the PAVE software delivered through a virtual-reality head-mounted display for an eight-week training course with three sessions per week, with a minimum planned sample of 15 subjects. The primary outcome is change in visual field area measured by semiautomated Goldmann-type kinetic perimetry (SKP), and the secondary outcome is change on the NEI Visual Function Questionnaire (NEI-VFQ). Baseline and post-therapy measurements will be compared to see if the VR regimen produces measurable field enlargement and improved self-reported visual function.
Why it matters
Potential benefit: If successful, PAVE could enlarge patients' usable visual field and improve everyday visual tasks such as navigation and reading.
How similar studies have gone: Prior visual-restoration and perceptual-learning programs have produced modest field or functional gains in some patients, but the PAVE parallactic VR approach is relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * This study will include patients at least 6 months after the CVA or TBI or brain surgery event and up to ten (10) years after onset * The patients shall have a definitive diagnosis of homonymous hemianopia or quadrantanopia or generalized constriction. Exclusion Criteria: * Presence of any physical, neurological, or mental disability that would interfere with receiving the therapy. * Concurrent use of another visual therapy * Concurrent use of medications judged to affect training (amphetamines, dopamine, etc.) * Presence of ocular or neurological conditions that would interfere with training or cause a visual impairment including no residual vision, disorders of the eye, non-optic nerve heteronymous visual field defects * Insufficient fixation ability * Use of life supporting external medical device such as infusion pumps, ventricular assist devices, etc. * Presence of active implantable medical device including but not limited to cardiac pacemakers, defibrillators, nerve stimulators, cochlear implants, etc. * Subjects with known photosensitive epilepsy. * Subjects with chronic active infections on the head and face should be excluded from the study * Patients with known immune disorders for whom an infection could be life threatening should be excluded from the study.
Where it's running
-
Dr. D. M. Fitzgerald & Associates
Cedar Rapids, Iowa, United States Recruiting -
Neuro-Vision Associates of North Texas
Prospect, Kentucky, United States Recruiting
Study contacts
- Principal investigator: DeAnn Fitzgerald, Doctor of Optometry — Dr. D. M. Fitzgerald & Associates
- Study coordinator: Michael Lynch, BSME
- Email: michael.lynch@neuroaeye.com
- Phone: 315-730-9842
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Multisensory neuromodulation to improve visual field loss after stroke
This will try combining audio-visual training with noninvasive brain stimulation (tDCS) to help people within three months of stroke who have homonymous hemianopsia improve their visual field and visual scanning.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.